LeMaitre Vascular Inc (NASDAQ:LMAT), a global provider of medical devices for the treatment of peripheral vascular disease, announced that Chairman and CEO, 10% Owner George Lemaitre sold 101,478 shares of the company on March 4, 2024. The transaction was filed with the SEC and can be found in the following SEC Filing.
According to the filing, the shares were sold at an average price of $68.43, resulting in a total value of approximately $6,941,635.34. Following this transaction, the insider's stake in LeMaitre Vascular Inc has been adjusted, as reflected in the company's insider trading history.
Over the past year, George Lemaitre has engaged in multiple transactions involving the company's stock. The insider has sold a total of 301,945 shares and has not made any purchases of the stock during this period.
The insider transaction history for LeMaitre Vascular Inc shows a pattern of sales by insiders over the past year, with 11 insider sells and no insider buys recorded.
In terms of valuation, LeMaitre Vascular Inc's shares were trading at $68.43 on the day of the sale, giving the company a market capitalization of $1.512 billion. The price-earnings ratio of the company stands at 56.13, which is above both the industry median of 27.64 and the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 1.11, indicating that LeMaitre Vascular Inc is considered Modestly Overvalued according to the GF Value. The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates from analysts.
Investors and stakeholders in LeMaitre Vascular Inc may consider the insider's recent transaction as part of their analysis when making investment decisions. It is important to note that insider trading activity, such as the sale by George Lemaitre, can provide insights into the company's performance and insider perspectives, but should not be the sole factor in investment strategies.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
